multiple myeloma. ‘403 claim 5 specifies that the antibodies used are CDR-grafted. ‘403 claim
7 specifies that the antibodies used are chimeric.
‘403 claims 2, 4, and 6 and ‘404 claim 7 relate to methods of treatment using antibodies
expressed and glycosylated by CHO cells where the expressed antibodies specifically bind to
CD4 antigen. ‘403 claim 4 specifies that the antibodies used are CDR-grafted. ‘403 claim 6
specifies that the antibodies used are chimeric.
‘405 claim 2 relates to a method of treatment for cancer that is non-Hodgkins lymphoma
using antibodies expressed and glycosylated by CHO cells.
‘405 claims 3 and 4 relate to methods of treatment for cancer that is multiple myeloma
using antibodies expressed and glycosylated by CHO cells (claim 3) where the expressed
antibodies specifically bind to a T-cell marker (claim 4).
‘405 claim 7 relates to methods of treatment for cancer using antibodies expressed and
glycosylated by CHO cells where the antibody specifically binds to CD33 or CD38 antigen.
‘404 claim 3 is directed to methods of treating autoimmune diseases using antibodies
expressed and glycosylated by CHO cells where the autoimmune disease “comprises multiple
sclerosis, graft vs. host disease, psoriasis, juvenile onset diabetes, Sjogrens’ disease, thyroid
disease, myasthenia gravis, transplant rejection or asthma.”
‘404 claim 4 relates to methods of treating a T-cell mediated disorder using antibodies
expressed and glycosylated by CHO cells where the T-cell mediated disorder “comprises severe
vasculitis, rheumatoid arthritis or systemic lupus.”
‘404 claim 5 depends on ‘404 claim 4 and specifies that the T-cell mediated disorder is
rheumatoid arthritis.
-27-
Page: Previous 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 Next
Last modified: November 3, 2007